Hypoxia drives HIF2-dependent reversible macrophage cell cycle entry
- Cell Rep. 2024 Jul 23;43(7):114471. doi: 10.1016/j.celrep.2024.114471.
- 1. Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK; Department of Medicine, University of Cambridge, Cambridge, UK. Electronic address: [email protected].
- 2. University of Oxford, Oxford, UK.
- 3. Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK; Department of Medicine, University of Cambridge, Cambridge, UK.
- 4. Babraham Institute, Cambridge, UK.
- 5. School of Clinical Medicine, University of Cambridge, Cambridge, UK.
- 6. Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK; Department of Medicine, University of Cambridge, Cambridge, UK; Africa Health Research Institute, Durban, KwaZulu Natal, South Africa. Electronic address: [email protected].
Low-oxygen conditions (hypoxia) have been associated primarily with cell-cycle arrest in dividing cells. Macrophages are typically quiescent in G0 but can proliferate in response to tissue signals. Here we show that hypoxia (1% oxygen tension) results in reversible entry into the cell cycle in macrophages. Cell cycle progression is largely limited to G0-G1/S phase transition with little progression to G2/M. This cell cycle transitioning is triggered by an HIF2α-directed transcriptional program. The response is accompanied by increased expression of cell-cycle-associated proteins, including CDK1, which is known to phosphorylate SAMHD1 at T592 and thereby regulate Antiviral activity. Prolyl hydroxylase (PHD) inhibitors are able to recapitulate HIF2α-dependent cell cycle entry in macrophages. Finally, tumor-associated macrophages (TAMs) in lung cancers exhibit transcriptomic profiles representing responses to low oxygen and cell cycle progression at the single-cell level. These findings have implications for inflammation and tumor progression/metastasis where low-oxygen environments are common.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: HIF/HIF Prolyl-HydroxylaseResearch Areas: Cancer
-
target: HIF/HIF Prolyl-HydroxylaseResearch Areas: Cardiovascular Disease